Author : Vinod kumar p
Keyword : Ulcerative colitis; crohn’s disease; vascular cell adhesion molecule-1; mucosal addressin cell adhesion molecule-1; inflammatory bowel disease
Subject : Pharmacology
Article Type : Review article
DOI : 10.31531/2231-5896.1000111
Article QR Code
Article File : Full Text PDF
Abstract : Inflammatory bowel disease is a chronic inflammatory disease of which the etiology is unknown. Ulcerative colitis and Crohn's disease are the two main entities of inflammatory bowel disease that are challenging clinicians. In addition to tumor necrosis factor blockers, this overview summarizes current and future new drugs, in the treatment of inflammatory bowel disease according to their goals. The infiltration of lymphocytes into the intestinal lining is a target for therapeutic purposes in inflammatory the intestinal lining is a target for therapeutic purposes in inflammatory bowel disease. The vascular cell adhesion molecule-1 and the mucosal addressin cell adhesion molecule-1 are a family of integrins for the alpha4 that are specifically expressed in the alimentary canal on vascular endothelial cells. In Crohn's disease, the alpha4beta7 integrin, and its endothelial receptor, the mucosal addressin cell adhesion molecule-1, have proven to be a relevant factor in the development of chronic intestinal inflammation. New biological and chemical drugs are emerging, with additional molecules pending approval.
Article by : P VINOD KUMAR
Article add date : 2021-05-20
How to cite : Vinod kumar p. (2021-May-20). Is the new approach in inflammatory bowel disease treat-to-target?. retrieved from https://www.openacessjournal.com/abstract/733